JPH09510346A - 哺乳動物細胞における新生物形質転換の制御に関連する遺伝子および遺伝学的因子 - Google Patents

哺乳動物細胞における新生物形質転換の制御に関連する遺伝子および遺伝学的因子

Info

Publication number
JPH09510346A
JPH09510346A JP7522985A JP52298595A JPH09510346A JP H09510346 A JPH09510346 A JP H09510346A JP 7522985 A JP7522985 A JP 7522985A JP 52298595 A JP52298595 A JP 52298595A JP H09510346 A JPH09510346 A JP H09510346A
Authority
JP
Japan
Prior art keywords
cells
gse
gene
protein
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP7522985A
Other languages
English (en)
Japanese (ja)
Inventor
グドコフ，アンドレイ
カザロフ，アレクサンダー
マゾ，イルヤ
ロニンソン，アイゴール・ビー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois at Urbana Champaign
Original Assignee
University of Illinois at Urbana Champaign
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana Champaign filed Critical University of Illinois at Urbana Champaign
Publication of JPH09510346A publication Critical patent/JPH09510346A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y599/00—Other isomerases (5.99)
    • C12Y599/01—Other isomerases (5.99.1)
    • C12Y599/01003—DNA topoisomerase (ATP-hydrolysing) (5.99.1.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
JP7522985A 1994-03-02 1995-03-01 哺乳動物細胞における新生物形質転換の制御に関連する遺伝子および遺伝学的因子 Withdrawn JPH09510346A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/204,740 1994-03-02
US08/204,740 US5753432A (en) 1990-10-19 1994-03-02 Genes and genetic elements associated with control of neoplastic transformation in mammalian cells
PCT/US1995/002521 WO1995023855A2 (en) 1994-03-02 1995-03-01 Genes and genetic elements associated with control of neoplastic transformation in mammalian cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004127092A Division JP2004344163A (ja) 1994-03-02 2004-04-22 哺乳動物細胞における新生物形質転換の制御に関連する遺伝子および遺伝学的因子

Publications (1)

Publication Number Publication Date
JPH09510346A true JPH09510346A (ja) 1997-10-21

Family

ID=22759235

Family Applications (2)

Application Number Title Priority Date Filing Date
JP7522985A Withdrawn JPH09510346A (ja) 1994-03-02 1995-03-01 哺乳動物細胞における新生物形質転換の制御に関連する遺伝子および遺伝学的因子
JP2004127092A Pending JP2004344163A (ja) 1994-03-02 2004-04-22 哺乳動物細胞における新生物形質転換の制御に関連する遺伝子および遺伝学的因子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004127092A Pending JP2004344163A (ja) 1994-03-02 2004-04-22 哺乳動物細胞における新生物形質転換の制御に関連する遺伝子および遺伝学的因子

Country Status (9)

Country Link
US (5) US5753432A (https=)
EP (1) EP0749477A1 (https=)
JP (2) JPH09510346A (https=)
KR (1) KR100255582B1 (https=)
AU (1) AU689869B2 (https=)
CA (1) CA2184580A1 (https=)
NO (1) NO963627L (https=)
WO (1) WO1995023855A2 (https=)
ZA (1) ZA951731B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326488B1 (en) * 1990-10-19 2001-12-04 Board Of Trustees Of University Of Illinois Gene and genetic elements associated with sensitivity to chemotherapeutic drugs
US6268134B1 (en) * 1993-09-07 2001-07-31 Board Of Trustees Of University Of Il Method and applications for efficient genetic suppressor elements
US6747133B1 (en) 1995-12-08 2004-06-08 University Technologies International Inc. Antibodies against the tumor suppressor gene ING1
US6143522A (en) * 1995-12-08 2000-11-07 University Technologies International, Inc. Methods of modulating apoptosis
US6037121A (en) * 1995-12-08 2000-03-14 University Technologies International Inc. DNA sequence encoding a tumor suppressor gene
US6117633A (en) * 1995-12-08 2000-09-12 University Technologies International Inc. DNA sequence encoding the tumor suppressor gene ING1
US6060240A (en) * 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US6365347B1 (en) * 1997-04-11 2002-04-02 The Regents Of The University Of California Method for identifying disruptors of biological pathways using genetic selection
WO2000053743A1 (en) * 1999-03-12 2000-09-14 Gpc Biotech, Inc. Methods and reagents for identifying synthetic genetic elements
AU2001287273A1 (en) * 2000-03-24 2001-10-08 Maxygen, Inc. Methods for modulating cellular and organismal phenotypes
WO2001075178A2 (en) * 2000-04-04 2001-10-11 Enanta Pharmaceuticals, Inc. Methods for identifying peptide aptamers capable of altering a cell phenotype
JP2005516586A (ja) * 2001-07-20 2005-06-09 ボード オブ トラスティーズ オブ ザ ユニヴァースティ オブ イリノイ 癌の処置に対する遺伝子標的を同定するための試薬および方法
AU2002365031A1 (en) * 2001-08-10 2003-06-23 The Board Of Trustees Of The University Of Illinois Indirect fluctuation screening
US20040009156A1 (en) * 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
KR101258329B1 (ko) * 2008-04-18 2013-04-25 이 아이 듀폰 디 네모아 앤드 캄파니 Ｃｕ-함유 유리 프릿을 사용하는 저항 조성물
EP2424986A1 (en) 2009-04-27 2012-03-07 Roswell Park Cancer Institute Reagents and methods for producing bioactive secreted peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217889A (en) * 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
WO1993015743A1 (en) * 1992-02-18 1993-08-19 Baylor College Of Medicine Novel gene therapies employing antisense constructs
JP2731630B2 (ja) * 1992-02-19 1998-03-25 ベイラー・カレッジ・オブ・メディスン 細胞増殖のオリゴヌクレオチドの変調
DE69432120T2 (de) * 1993-03-09 2003-12-11 Univ Illinois Mit chemotherapeutische zusammensetzungenassoziierten genetischen suppressor-elementen

Also Published As

Publication number Publication date
US20020099028A1 (en) 2002-07-25
US6083745A (en) 2000-07-04
NO963627D0 (no) 1996-08-30
AU689869B2 (en) 1998-04-09
ZA951731B (en) 1995-12-27
KR970701780A (ko) 1997-04-12
CA2184580A1 (en) 1995-09-08
KR100255582B1 (ko) 2000-05-01
WO1995023855A3 (en) 1995-09-28
US6197521B1 (en) 2001-03-06
EP0749477A1 (en) 1996-12-27
AU1974095A (en) 1995-09-18
US6083746A (en) 2000-07-04
JP2004344163A (ja) 2004-12-09
NO963627L (no) 1996-10-22
US5753432A (en) 1998-05-19
WO1995023855A2 (en) 1995-09-08

Similar Documents

Publication Publication Date Title
Small et al. Neoplastic transformation by the human gene N-myc
JP2023123766A (ja) アルファウイルス新生抗原ベクター
Ryan et al. Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells
JPH09510346A (ja) 哺乳動物細胞における新生物形質転換の制御に関連する遺伝子および遺伝学的因子
Amstad et al. Neoplastic transformation of a human bronchial epithelial cell line by a recombinant retrovirus encoding viral Harvey ras
KR20210013105A (ko) 공유 항원
CA2315279A1 (en) 14-3-3.sigma. arrests the cell cycle
CA2044940A1 (en) Transdominant negative proto-oncogene
KR20230014694A (ko) 항원-코딩 카세트
Piwnica-Worms et al. Retrovirus shuttle vector for study of kinase activities of pp60c-src synthesized in vitro and overproduced in vivo
CN111187835A (zh) 胰腺癌的靶点erbb2及其在诊断和治疗中的应用
EP0694068B1 (en) Genetic suppressor elements associated with sensitivity to chemotherapeutic drugs
WO1996001899A1 (en) METHOD FOR IDENTIFYING NUCLEIC ACIDS ENCODING c-fos PROMOTER ACTIVATING PROTEINS
Kulke et al. Biological properties of the deer papillomavirus E5 gene in mouse C127 cells: growth transformation, induction of DNA synthesis, and activation of the platelet-derived growth factor receptor
WO2001057189A9 (en) Fas pathway genes
JPH11512294A (ja) 癌の治療、予防および発見を目的とする腫瘍細胞での蛋白ホスファターゼ２Ｃ−ＰＰ２Ｃα−発現の操作と検出
JPH09508006A (ja) キネシンと化学療法薬に対する感受性との関連
US6982313B2 (en) Genes and genetic elements associated with sensitivity to chemotherapeutic drugs
EP0920305B1 (en) Identification of genes altered in multiple myeloma
Gjerset et al. Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway
EP1115386B1 (en) Medicament for the treatment of infection
AU776955B2 (en) Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin
WO1999001465A1 (en) A senescence gene and its use in the treatment of cancer and other diseases
CA2227306A1 (en) Manipulation and detection of protein phosphatase 2c - pp2c.alpha. - expression in tumor cells for cancer therapy, prevention and detection
JPH09510104A (ja) 形質転換の進行の誘導性阻害剤を同定する方法

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20031224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040422

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20040701

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20040715

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070313